Dividends & Buybacks ·
Calidi Biotherapeutics, Inc. effected a reverse stock split of its common stock at a ratio of 1-for-16 to increase the…
CLDWWCalidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc. effected a reverse stock split of its common stock at a ratio of 1-for-16 to increase the per-share trading price and support continued listing on NYSE American. The split became effective on July 30, 2026, with split-adjusted trading commencing on July 31, 2026. Fractional shares were rounded up to the nearest whole share without cash payment. Post-split, approximately 2,445,396 Voting Common Stock and 9,375 Non-Voting Common Shares are outstanding out of 330 million authorized shares. Calidi Biotherapeutics operates in the biotechnology industry, developing immunotherapies for cancer treatment.